HAP Trading’s BridgeBio Pharma BBIO Stock Holding History

HAP Trading’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-38,039	Closed	-$1.04M	–	685
2024 Q1	$1.18M	Buy	+38,039	New	+$1.29M	0.13%	113
2023 Q3	–	Sell	-56,293	Closed	-$968K	–	1046
2023 Q2	$968K	Buy	+56,293	New	+$847K	0.17%	114
2022 Q1	–	Sell	-453,272	Closed	-$4.65M	–	2221
2021 Q4	$7.56M	Buy	453,272 +385,940	+573%	+$16.3M	0.21%	86
2021 Q3	$3.16M	Buy	67,332 +30,253	+82%	+$1.62M	0.1%	189
2021 Q2	$2.26M	Sell	37,079 -2,912	-7%	-$166K	0.07%	263
2021 Q1	$2.46M	Buy	+39,991	New	+$2.62M	0.13%	146

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HAP Trading's BBIO Position: Q2 2024 in Review

HAP Trading sold out of BridgeBio Pharma (BBIO) in Q2 2024, closing a stake of 38,039 shares — an estimated $1.04M sold.

HAP Trading first reported a position in BBIO in Q1 2021 and held it in 6 quarters. The position peaked at $7.56M in Q4 2021. 251 funds tracked by Wall St. Rank hold BBIO as of Q2 2024.

HAP Trading reported no remaining BridgeBio Pharma position as of Q2 2024 after selling out during the quarter.
HAP Trading sold 38,039 BridgeBio Pharma shares in Q2 2024, an estimated $1.04M.
HAP Trading first reported a position in BridgeBio Pharma in Q1 2021 and held it in 6 quarters.
HAP Trading's BridgeBio Pharma position peaked at $7.56M in Q4 2021.
251 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2024.

Based on HAP Trading's 13F filing for Q2 2024, filed 14 Aug 2024.